GJ
George M Jenkins (Director) filed 3 Form 4 reports in the trailing twelve months (1 purchase, 2 sales), most often in Palvella Therapeutics, Inc. (PVLA). Across 1 priced purchase filing, the average 21-session return was -23.3% from execution and -21.8% from disclosure (delay-adjusted; derived). The largest single filing was $4.0M of PVLA (26,677 sh across 7 lots, as filed), executed Sep 11. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-23.3%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-21.8%
same 1 filings, from disclosure
Filings, ttm
3
1 buys · 2 sells
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$7.8M
shares × price, as filed
Last traded
Oct 14
Filed Oct 14
Median ADV $37.6M across their filed names
Open performance→Volume by month
Buys $500K
Sells $7.3M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
PVLARecent filings
PVLASALE
Palvella Therapeutics, Inc.
View filing →
$3.3M25,343 sh across 13 lots
Exec Oct 12
Filed Oct 14 · 7:14 PM ET PVLASALE Palvella Therapeutics, Inc. View filing → $4.0M
26,677 sh across 7 lots
Exec Sep 11
Filed Sep 15 · 9:15 PM ET PVLAPURCHASE Palvella Therapeutics, Inc. View filing → $500K
4,000 sh × $125.00
Exec Feb 27
Filed Mar 2 · 8:00 AM ET